NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23
Meeting will address Phase 2 study design and potential regulatory pathways for oral NEO212
Meeting will address Phase 2 study design and potential regulatory pathways for oral NEO212
Objective response rate was 12.5% (3 of 24 patients) by RANO 2.0, compared with 8.3% (2 of 24 patients) in the August
Latest purchase of 30,000 shares brings year-to-date total to 371,000 shares
CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the
2026 open-market purchases total 271,000 shares for approximately $1.11 million
Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual
CALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the
Segment to air Sunday, October 25, at 5:30 p.m. ET on Fox Business Network
Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment
Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed
With UAE authorizations for both lead drug candidates, NeOnc brings a clinical development perspective to discussions
Appointment strengthens financial governance and supports NeOnc’s clinical development and expansion in Abu Dhabi
